Costas A. Lyssiotis, PhD, with his sponsor Lewis C. Cantley, PhD, at Beth Israel Deaconess Medical Center, Boston, Massachusetts, is studying the underlying differences in cellular metabolism between cancer cells and normal cells. In particular, he is interested in understanding (i) how cancer cells rewire their metabolic networks to satisfy the demands of continuous proliferation and (ii) what happens to cancerous cells when they are forced to behave metabolically like normal cells. While his initial studies will be aimed at addressing these questions in breast cancer, these studies have the potential to provide new ways to treat many types of cancers.
Dale Muzzey, PhD [HHMI Fellow] with his sponsor Jonathan S. Weissman, PhD, at the University of California, San Francisco, California, is studying how both the sequence and structure of mRNAs affect the efficiency by which they are translated into protein in the yeast Candida albicans. Defects in mRNA translation have been linked to several cancers, and he hopes to reveal features of translational control that generalize to humans. Additionally, his project may highlight potential ways to combat Candida infections, which frequently afflict immune-compromised cancer patients undergoing therapy.
Jason A. Reuter, PhD, with his sponsor Michael P. Snyder, PhD, at Stanford University, Stanford, California, is investigating the role of a new class of RNAs (long non-protein-coding RNAs) in regulation of cellular differentiation, a process that generates the specialized cell types found throughout our bodies. Aberrant differentiation is commonly observed in human tumors; poorly differentiated tumor cells are associated with the worst prognosis. Research on the regulation of normal cellular differentiation may, therefore, provide insight into the mechanisms underlying tumor progression. These RNAs may also represe
|Contact: Yung S. Lie, PhD|
Damon Runyon Cancer Research Foundation